$Efficacy and Safety of TACE Combined With Sorafenib Plus Immune Checkpoint Inhibitors for the Treatment of Intermediate and Advanced TACE-Refractory Hepatocellular Carcinoma: A Retrospective Study$

Efficacy and Safety of TACE Combined With Sorafenib Plus Immune Checkpoint Inhibitors for the Treatment of Intermediate and Advanced TACE-Refractory Hepatocellular Carcinoma: A Retrospective Study

Purpose: The study aims to retrospectively investigate the efficacy and safety of sorafenib combined with transarterial chemoembolization (TACE) (TACE+Sor) vs. TACE combined with sorafenib plus immune checkpoint inhibitors (TACE+Sor+ICIs) in treating intermediate and advanced TACE-refractory hepatoc...

Full description

Bibliographic Details
Main Authors:	Liyun Zheng, Shiji Fang, Fazong Wu, Weiqian Chen, Minjiang Chen, Qiaoyou Weng, Xulu Wu, Jingjing Song, Zhongwei Zhao, Jiansong Ji
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-01-01
Series:	Frontiers in Molecular Biosciences
Subjects:	TACE-refractory immune checkpoint inhibitors sorafenib transarterial chemoembolization progression-free survival overall survival
Online Access:	https://www.frontiersin.org/articles/10.3389/fmolb.2020.609322/full

Similar Items

Effects of Early TACE Refractoriness on Survival in Patients with Hepatocellular Carcinoma: A Real-World Study
by: Yang C, et al.
Published: (2022-07-01)

TACE responser NDRG1 acts as a guardian against ferroptosis to drive tumorgenesis and metastasis in HCC
by: Bufu Tang, et al.
Published: (2023-05-01)

The role of scheduled second TACE in early-stage hepatocellular carcinoma with complete response to initial TACE
by: Jung Hee Kim, et al.
Published: (2017-03-01)

Initial Transarterial Chemoembolization (TACE) Using HepaSpheres 20–40 µm and Subsequent Lipiodol TACE in Patients with Hepatocellular Carcinoma > 5 cm
by: Su Min Cho, et al.
Published: (2021-04-01)

Comparing the effectiveness and safety of Sorafenib plus TACE with Apatinib plus TACE for treating patients with unresectable hepatocellular carcinoma: a multicentre propensity score matching study
by: Liang Yin, et al.
Published: (2023-05-01)

Efficacy and safety of transarterial chemoembolization plus sorafenib in patients with recurrent hepatocellular carcinoma after liver transplantation
by: Xia Zhang, et al.
Published: (2023-01-01)

Association between transarterial chemoembolization refractoriness and prognosis in Chinese patients with hepatocellular carcinoma: a large retrospective cohort study
by: Qinxue Sun, et al.
Published: (2025-01-01)

Efficacy comparison of optimal treatments for hepatocellular carcinoma patients with portal vein tumor thrombus
by: Yu Zhang, et al.
Published: (2022-01-01)

Development of TACE Refractoriness Scores in Hepatocellular Carcinoma
by: Li Chen, et al.
Published: (2021-03-01)

Optimizing outcomes in HCC: Comment on “optimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis” by Jiang et al.
by: Alessandro Rizzo
Published: (2021-12-01)

Evaluation of models to predict prognosis in patients with advanced hepatocellular carcinoma treated with TACE combined with apatinib
by: Fang Sun, et al.
Published: (2024-04-01)

Cone-beam CT acquisition during transradial TACE made easy; use of the swivel arm board
by: Pua, Uei, et al.
Published: (2018)

FAIL-T (AFP, AST, tumor sIze, ALT, and Tumor number): a model to predict intermediate-stage HCC patients who are not good candidates for TACE
by: Apichat Kaewdech, et al.
Published: (2023-05-01)

Efficacy and Safety of TACE Combined with Regorafenib Plus PD-1 Inhibitor in the Treatment of Hepatocellular Carcinoma After Sorafenib Resistance
by: Zou X, et al.
Published: (2023-02-01)

A Radiomics Signature-Based Nomogram to Predict the Progression-Free Survival of Patients With Hepatocellular Carcinoma After Transcatheter Arterial Chemoembolization Plus Radiofrequency Ablation
by: Shiji Fang, et al.
Published: (2021-08-01)

Tumor Hypervascularity and hand-foot-skin reaction predict better outcomes in combination treatment of TACE and Sorafenib for intermediate hepatocellular carcinoma
by: Enxin Wang, et al.
Published: (2019-04-01)

TACE-assisted multi-image guided radiofrequency ablation for the treatment of single hepatocellular carcinoma ≤ 5 cm: a retrospective study
by: Yong Xie, et al.
Published: (2024-04-01)

A Machine Learning Model for Predicting Prognosis in HCC Patients With Diabetes After TACE
by: Wu L, et al.
Published: (2025-01-01)

Identify optimal HAP series scores for unresectable HCC patients undergoing TACE plus sorafenib: A Chinese multicenter observational study
by: Yejing Zhu, et al.
Published: (2023-01-01)

Transarterial Chemoembolization and Sorafenib Combined with Microwave Ablation for Advanced Primary Hepatocellular Carcinoma: A Preliminary Investigation of Safety and Efficacy
by: Ni JY, et al.
Published: (2019-11-01)

Effectiveness and safety of brucea javanica oil assisted TACE versus TACE in the treatment of liver cancer: a systematic review and meta-analysis of randomized controlled trials
by: Zhi-Hai Wu, et al.
Published: (2024-06-01)

Prospective study of TACE combined with sorafenib vs TACE combined with 125I seed implantation in the treatment of hepatocellular carcinoma with portal vein tumor thrombus and arterioportal fistulas
by: Xiao-Hui Zhao, et al.
Published: (2022-10-01)

Efficacy of adjuvant TACE on the prognosis of patients with HCC after hepatectomy: a multicenter propensity score matching from China
by: Zhao Wu, et al.
Published: (2023-04-01)

Efficacy, safety, and biomarker analysis of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a real-world study
by: Lingzhan Meng, et al.
Published: (2024-11-01)

Balloon occluded TACE (B-TACE) vs DEM-TACE for HCC: a single center retrospective case control study
by: Pierleone Lucatelli, et al.
Published: (2021-02-01)

Development and Validation of TACE Refractoriness-Related Diagnostic and Prognostic Scores and Characterization of Tumor Microenvironment Infiltration in Hepatocellular Carcinoma
by: Qifan He, et al.
Published: (2022-04-01)

Comparison of local tumor control in patients with HCC treated with SBRT or TACE: a propensity score analysis
by: Dominik Bettinger, et al.
Published: (2018-08-01)

Prognosis of transarterial chemoembolization-sorafenib compared to transarterial chemoembolization-alone in hepatocellular carcinoma stage C: a systematic review
by: Rahmad Mulyadi, et al.
Published: (2024-05-01)

Transarterial Chemoembolization Combined with Sorafenib in Patients with BCLC Stage C Hepatocellular Carcinoma
by: Liu KC, et al.
Published: (2020-08-01)

Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A systematic review and meta-analysis
by: Jun-Ning Liu, et al.
Published: (2023-02-01)

Corrigendum: Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis
by: Jun-Ning Liu, et al.
Published: (2023-06-01)

Experience with Sorafenib in 3 Hospitals in Sao Paulo
by: Rogério Camargo-Pinheiro-Alves, et al.
Published: (2019-01-01)

TACE Plus Lenvatinib Versus TACE Plus Sorafenib for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Prospective Cohort Study
by: Biao Yang, et al.
Published: (2021-12-01)

Efficacy and safety analysis of dexamethasone-lipiodol emulsion in prevention of post-embolization syndrome after TACE: a retrospective analysis
by: Haohao Lu, et al.
Published: (2021-06-01)

BCLC-B hepatocellular carcinoma treatment or when should the systemic therapy be started
by: V. V. Breder, et al.
Published: (2018-07-01)

Arterial enhancement fraction in evaluating the therapeutic effect and survival for hepatocellular carcinoma patients treated with DEB-TACE
by: Bin Chai, et al.
Published: (2022-07-01)

Systemic Inflammation Response Index is a Prognostic Risk Factor in Patients with Hepatocellular Carcinoma Undergoing TACE
by: Wang TC, et al.
Published: (2021-06-01)

Single medium-sized hepatocellular carcinoma treated with sequential conventional transarterial chemoembolization (cTACE) and microwave ablation at 4 weeks versus cTACE alone: a propensity score
by: Zi-yi Zhu, et al.
Published: (2022-06-01)

Multidisciplinary Taiwan consensus for the use of conventional TACE in hepatocellular carcinoma treatment
by: Pi-Yi Chang, et al.
Published: (2023-06-01)

TACE versus TACE + entecavir versus TACE + tenofovir in the treatment of HBV associated hepatocellular carcinoma
by: Haohao Lu, et al.
Published: (2023-03-01)